Idera Pharmaceuticals Inc (NASDAQ:IDRA) rallied 10.52%, the company recently presented its new pre- clinical data that demonstrates the ability of the TLR or Toll-like receptor antagonist, IMO-8400, for inhibiting survival and the proliferation of the B-cell lymphoma cells that harbor the oncogenic MYD88- L265P genetic mutation. The data adds to the increasing body of research that supports IDRA’s efforts to develop its IMO-8400 for treating the genetically-defined forms of its B-cell lymphoma. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares after opening at $2.92 moved to $3.09 on last trade day and at the end of the day closed at $2.77. Company price to sales ratio in past twelve months was calculated as 4853.39 and price to cash ratio as 7.76.Idera Pharmaceuticals Inc (NASDAQ:IDRA) showed a negative weekly performance of -23.27%.
Money gram International Inc (NASDAQ:MGI) is showcasing superior growth in its money transfer business due to increasing demand, generating huge transaction volumes by penetrating into high-growth potential markets globally. By 2013-end, the company had expanded its worldwide agent network two-fold since 2007.Moneygram International Inc (NASDAQ:MGI) shares fell -17.68% in last trading session and ended the day on $14.81. MGI return on equity ratio is recorded as -12.80% and its return on assets is 1.10%. Moneygram International Inc (NASDAQ:MGI) yearly performance is -8.01%.
Net 1 UEPS (NASDAQ:UEPS) dropped Thursday after The Constitutional Court of South Africa, the nation’s highest court, ordered the cancellation of a contract awarded to the electronic payment systems technology company. The court ordered the government to open a new tender to disseminate social welfare grants just four months after it invalidated a $947 million contract won by Net 1. The court permitted Net 1 to continue providing grants to millions of pensioners on the state’s behalf until the issuing of a new five-year tender, the company announced Thursday. Net 1 UEPS Technologies Inc (NASDAQ:UEPS) shares moved down -5.52% in last trading session and was closed at. $8.98, while trading in range of $ 7.03 – 9.18. Net 1 UEPS Technologies Inc (NASDAQ:UEPS) year to date (YTD) performance is 2.92
Zalicus Inc (NASDAQ:ZLCS) revealed it had confirmed a deal with Epirus Biopharmaceuticals for a merger of the latter with a Zalicus subsidiary in an all-stock transaction. The merger will result in Zalicus being renamed and working under the management of Epirus Biopharmaceuticals. The leadership of the newly formed entity will be led by the current President and CEO of Epirus, Amit Munshi. Zalicus Inc (NASDAQ:ZLCS) company shares ended up $1.21. Zalicus Inc (NASDAQ:ZLCS) distance from 50-day simple moving average (SMA50) is -11.16%. Analysts mean target price for the company is $1.20.
Leave a Reply